6. Glynn, J. P., Moloney, J. B., Chirigos, M. A., and Goldin, A. Bio logical Interrelationships in the Chemotherapy of Moloney Virus.
Hydronephrosis Hydrocalycosis Hydronephrosis Hydroureteronephrosis Excludes: congenital hydronephrosis 753.29 ; hydroureter 593.5 ; 592 Calculus of kidney and ureter Excludes: nephrocalcinosis 275.49 ; 592.0 Calculus of kidney Nephrolithiasis NOS Renal calculus or stone Staghorn calculus Stone in kidney uric acid nephrolithiasis 274.11 ; Calculus of ureter Ureteric stone Ureterolithiasis Urinary calculus, unspecified. Ince the first AHA Science Advisory "Fish Consumption, Fish Oil, Lipids, and Coronary Heart Disease, "1 important new findings, including evidence from randomized controlled trials RCTs ; , have been reported about the beneficial effects of omega-3 or n-3 ; fatty acids on cardiovascular disease CVD ; in patients with preexisting CVD as well as in healthy individuals.2 New information about how omega-3 fatty acids affect cardiac function including antiarrhythmic effects ; , hemodynamics cardiac mechanics ; , and arterial endothelial function have helped clarify potential mechanisms of action. The present Statement will address distinctions between plant-derived -linolenic acid, C18: 3n-3 ; and marine-derived eicosapentaenoic acid, C20: 5n-3 [EPA] and docosahexaenoic acid, C22: 6n-3 [DHA] ; omega-3 fatty acids. Unless otherwise noted, the term omega-3 fatty acids will refer to the latter. ; Evidence from epidemiological studies and RCTs will be reviewed, and recommendations reflecting the current state of knowledge will be made with regard to both fish consumption and omega-3 fatty acid plant- and marine-derived ; supplementation. This will be done in the context of recent guidance issued by the US Environmental Protection Agency and the Food and Drug Administration FDA ; about the presence of environmental contaminants in certain species of fish.

Procedures. The attending surgeons are responsible to assure continuity of care provided to patients. ROLES AND RESPONSIBILITIES: The Department Chair and Program Director are responsible for implementation of and compliance with these requirements. The attending surgeon is responsible for, and must be familiar with, the care provided to the patient as exemplified by the following: 1 ; Direct the care of the patient and provide the appropriate level of supervision based on the nature of the patient's condition, the likelihood of major changes in the management plan, the complexity of care, and the experience and judgment of the resident being supervised. Documentation of this supervision will be via progress note, or countersignature thereof, or reflected within, the resident's progress note at a frequency appropriate to the patient's condition. In all cases where the provision of supervision is reflected within the resident's progress note, the note shall include the name of the attending surgeon with whom the case was discussed and the nature of that discussion. 2 ; Meet the patient early in the course of care for inpatients, within 24 hours of admission ; and document, in a progress note, concurrence with the resident's initial diagnoses and treatment plan. At a minimum, the progress note must state such concurrence and be properly signed and dated. If a patient is admitted for non-emergent care, a resident, who is authorized to act as a teaching assistant, may evaluate the patient and discuss the patient's circumstances via telephone with an appropriate attending surgeon. This discussion will be documented in the patient record. 3 ; Participate in rounds. Participation in bedside rounds does not require that the attending surgeon see every patient in person each day. It does require physical presence of the attending in the facility for sufficient time to provide appropriate supervision to residents. A variety of face-to-face interactions such as chart rounds, x-ray review sessions, pre-op reviews, or informal patient discussions fulfill this requirement. 4 ; Assure that all technically complex diagnostic and therapeutic procedures which carry a significant risk to the patient are: a ; medically indicated; b ; explained to the patient; c ; appropriately executed and interpreted; and d ; evaluated for appropriateness, effectiveness and required follow-up. Evidence of this assurance will be documented in the patient's record via a progress note s ; , or Countersignature thereof, or reflected within, the resident's progress note s ; . 5 ; Assure that discharge, or transfer, of the patient from an integrated or affiliated hospital or clinic is appropriate based on the specific circumstances of the patient's diagnoses and treatment. The patient will be provided appropriate information regarding prescribed therapeutic regimen, including specifics on physical activity, medications, diet, functional status, and follow-up plans. At a minimum, evidence of this assurance will be documented by countersignature of the hospital discharge summary or clinic discharge note. 6 ; Assure residents are given the opportunity to contribute to discussions in committees where.